blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4151221

EP4151221 - COMBINATION COMPRISING TRICYCLE COMPOUND AND USE THEREOF IN PREPARATION OF MEDICAMENT FOR TREATING HBV [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  17.02.2023
Database last updated on 03.10.2024
FormerThe international publication has been made
Status updated on  19.11.2021
Most recent event   Tooltip06.05.2024The date on which the examining division becomes responsible, has been established 
06.05.2024Amendment by applicant 
Applicant(s)For all designated states
Fujian Akeylink Biotechnology Co., Ltd.
2F, Comprehensive Office Building
Building 1-7, Fuyuan Industrial Zone
Zherong County
Ningde, Fujian 355300 / CN
[2023/12]
Inventor(s)01 / WU, Wenqiang
Ningde, Fujian 355300 / CN
02 / ZHANG, Dong
Ningde, Fujian 355300 / CN
03 / MA, Zhiqiang
Ningde, Fujian 355300 / CN
04 / ZHOU, Yixin
Ningde, Fujian 355300 / CN
05 / MAO, John
Ningde, Fujian 355300 / CN
06 / JIANG, Zhigan
Shanghai 200131 / CN
07 / WANG, Jing
Shanghai 200131 / CN
08 / HE, Haiying
Shanghai 200131 / CN
 [2023/12]
Representative(s)dompatent von Kreisler Selting Werner - Partnerschaft von Patent- und Rechtsanwälten mbB
Deichmannhaus am Dom
Bahnhofsvorplatz 1
50667 Köln / DE
[2023/12]
Application number, filing date21804833.814.05.2021
[2023/12]
WO2021CN93769
Priority number, dateCN20201041276015.05.2020         Original published format: CN202010412760
CN20201163337331.12.2020         Original published format: CN202011633373
[2023/12]
Filing languageZH
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021228213
Date:18.11.2021
Language:ZH
[2021/46]
Type: A1 Application with search report 
No.:EP4151221
Date:22.03.2023
Language:EN
[2023/12]
Search report(s)International search report - published on:CN18.11.2021
(Supplementary) European search report - dispatched on:EP17.10.2023
ClassificationIPC:A61K31/55, A61K31/33, A61K31/395, A61K31/40, A61K31/5365, A61P1/16, A61P31/20
[2023/46]
CPC:
A61P1/16 (EP); A61K31/554 (EP,US); A61K31/513 (US);
A61K31/522 (EP,US); A61K31/5365 (EP,US); A61K31/553 (EP,US);
A61K31/675 (US); A61K31/683 (EP); A61K45/06 (EP,US);
A61P31/20 (EP,US) (-)
C-Set:
A61K31/522, A61K2300/00 (EP);
A61K31/5365, A61K2300/00 (EP);
A61K31/553, A61K2300/00 (EP);
A61K31/554, A61K2300/00 (EP);
A61K31/683, A61K2300/00 (EP)
(-)
Former IPC [2023/12]A61K31/55, A61K31/33, A61K31/395, A61K31/40, A61K31/5365, C07D487/00, C07D471/04, C07D498/04, A61P1/16, A61P31/20
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/12]
TitleGerman:KOMBINATION MIT EINER TRICYCLISCHEN VERBINDUNG UND VERWENDUNG DAVON BEI DER HERSTELLUNG EINES MEDIKAMENTS ZUR BEHANDLUNG VON HBV[2023/12]
English:COMBINATION COMPRISING TRICYCLE COMPOUND AND USE THEREOF IN PREPARATION OF MEDICAMENT FOR TREATING HBV[2023/12]
French:COMBINAISON COMPRENANT UN COMPOSÉ TRICYCLIQUE ET SON UTILISATION DANS LA PRÉPARATION D'UN MÉDICAMENT POUR LE TRAITEMENT DU VHB[2023/12]
Entry into regional phase15.12.2022Translation filed 
15.12.2022National basic fee paid 
15.12.2022Search fee paid 
15.12.2022Designation fee(s) paid 
15.12.2022Examination fee paid 
Examination procedure15.12.2022Examination requested  [2023/12]
03.05.2024Amendment by applicant (claims and/or description)
03.05.2024Date on which the examining division has become responsible
Fees paidRenewal fee
29.03.2023Renewal fee patent year 03
15.03.2024Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[Y]EP3587420  (FUJIAN COSUNTER PHARMACEUTICAL CO LTD [CN]) [Y] 1-15 * Embodiment 85 * * paragraph [0558] - paragraph [0560] *;
 [Y]EP3590942  (FUJIAN COSUNTER PHARMACEUTICAL CO LTD [CN], et al) [Y] 1-15 * claim 1 *;
 [Y]EP3632914  (FUJIAN COSUNTER PHARMACEUTICAL CO LTD [CN], et al) [Y] 1-15 * claim 1 * * Test embodiment 7 *;
 [Y]  - AZIZ MUNEBA ET AL, "Predictors of Therapeutic Outcome to Nucleotide Reverse Transcriptase Inhibitor in Hepatitis B Patients", VIRAL IMMUNOLOGY, (201811), vol. 31, no. 9, ISSN 0882-8245, pages 632 - 638, XP093089667 [Y] 1-15 * page 632, abstract *

DOI:   http://dx.doi.org/10.1089/vim.2018.0022
 [Y]  - YANG L ET AL, "Identification and Characterization of Pyrimidinediones as Potent Non-nucleoside Reverse Transcriptase Inhibitors of Hepatitis B virus", ANTIVIRAL RESEARCH, ELSEVIER BV, NL, vol. 82, no. 2, doi:10.1016/J.ANTIVIRAL.2009.02.058, ISSN 0166-3542, (20090501), page A32, (20090501), XP026193219 [Y] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1016/j.antiviral.2009.02.058
International search[A]CN102060786  (UNIV TIANJIN) [A] 1-32 * entire document *;
 [A]CN105102451  (JANSSEN R & D IRELAND) [A] 1-32 * entire document *;
 [A]CN106255684  (NOVIRA THERAPEUTICS INC) [A] 1-32 * entire document *;
 [A]CN106459032  (HOFFMANN LA ROCHE) [A] 1-32* entire document *;
 [Y]WO2018153285  (FUJIAN COSUNTER PHARMACEUTICAL CO LTD [CN], et al) [Y] 1-32 * claims 1, 14 and 17 *;
 [Y]WO2018161960  (FUJIAN COSUNTER PHARMACEUTICAL CO LTD [CN], et al) [Y] 1-32 * claims 1, 20-21, 23 *;
 [Y]WO2018214875  (FUJIAN COSUNTER PHARMACEUTICAL CO LTD [CN], et al) [Y] 1-32 * claims 1, 16, 19-20 *;
 [A]WO2020038456  (FUJIAN COSUNTER PHARMACEUTICAL CO LTD [CN]) [A] 1-32 * entire document *;
 [Y]  - WANG Hong-liang; LIU Xia-ling; CAO Shuang, "Anti-Hepatitis B Virus Drugs: Research Advances", Journal of International Pharmaceutical Research, CN , (20160229), vol. 43, no. 1, doi:10.13220/j.cnki.jipr.2016.01.020, pages 134 - 138, XP009531790 [Y] 1-32 * pp. 134-138 *

DOI:   http://dx.doi.org/10.13220/j.cnki.jipr.2016.01.020
by applicantWO2018153285
 WO2018161960
 WO2018214875
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.